Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer

Cancer

Volumn 117, Issue 24, 2011, Pages 5461-5468

  McArthur, Heather L ^a   Mahoney, Kathleen M ^b   Morris, Patrick G ^a   Patil, Sujata ^a   Jacks, Lindsay M ^a   Howard, Jane ^a   Norton, Larry ^a   Hudis, Clifford A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NewYork Presbyterian/Weill Cornell   (United States)

Author keywords

breast cancer; HER2; node negative; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; ONCOGENE NEU; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT REFUSAL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 82955233117     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26171     Document Type: Article

References (17)

1. Slamon D, Clark GM, Wong S, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-182. (Pubitemid 17231334)
2. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118-145. (Pubitemid 350003059)
3. Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol. 2009; 27: 5693-5699.
4. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009; 27: 5700-5706.
5. Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 2009; 26: 5697-5704.
6. Hudis CA,. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med. 2007; 357: 39-51. (Pubitemid 47026733)
7. Romond EH, Perez EA, Bryant J, et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer-combined analysis of NSABP-B31/NCCTG-N9831. Paper presented at: Annual Meeting of American Society of Clinical Oncology; Orlando, FL, May 13-17, 2005.
8. Piccart-Gebhart M,. First results of the HERA trial. Paper presented at: Annual Meeting of American Society of Clinical Oncology; Orlando, FL, May 13-17, 2005.
9. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-1684. (Pubitemid 41464706)
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672. (Pubitemid 41464705)
11. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Paper presented at: San Antonio Breast Cancer Symposium; 2005; San Antonio, TX, December 8-11, 2005.
12. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354: 809-820. (Pubitemid 43290919)
13. Edge SB, Byrd DR, Compton CC, et al. American Joint Committee on Cancer (AJCC) cancer staging manual. 7th ed. Chicago, IL: Springer; 2010.
14. Rodrigues MJ, Wassermann J, Albiges-Sauvin L, et al. Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas. J Clin Oncol. 2010; 28: e541-542.
15. Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol. 2008; 19: 1090-1096. (Pubitemid 351796334)
16. American Cancer Society. Cancer facts and figures 2009. Available at: Accessed January 23, 2011.
17. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007; 25: 2127-2132. (Pubitemid 46972801)